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Summary.-Purified C3a, a cleavage product of the third component of complement,
was incubated with various cell types of human and mouse origin. All the tumour
cell types tested were lysed by low concentrations of C3a, whereas normal human
lymphocytes were relatively resistant. No lysis was produced by C3 or C3b. The
possible role of C3a in immunity against tumours is discussed.
THE IMMUNE SYSTEM can kill tumour
cells or inhibit their growth in a variety
of ways, including antibody and comple-
ment (Old et al., 1967), lysis by contact
with immune T-lymphocytes (Cerottini
and Brunner, 1974), antibody-dependent
cell-mediated cytotoxicity (Perlmann and
Holm, 1969), contact with armed macro-
phages (Evans and Alexander, 1971) and
incubation with soluble products, such as
lymphotoxin, a mediator released into the
supernatant when sensitized lymphocytes
are incubated with antigen (Eifel, Walker
and Lucas, 1975) and a cytotoxic factor
liberated from activated macrophages
(Sethi and Brandis, 1975; Currie and
Basham, 1975). To this list we add another
mechanism, action of the complement
cleavage product C3a.
When complement is activated, by
either the classical or the alternative
pathway, C3 is cleaved into a small piece,
C3a, and a large piece, C3b. C3a, one
of the anaphylatoxins, induces the selec-
tive release of histamine from mast cells
(Dias da Silva, Eisele and Lepow, 1967;
Cochrane and Miiller-Eberhard, 1968) and
contraction of smooth muscle via hista-
mine, as well as probably by a direct
interaction with the muscle cell plasma
membrane (Bokisch and Miiller-Eberhard,
1970). In a recent investigation of the
effects of complement cleavage products
on macrophages in culture, we observed
that purified C3b induces enzyme release
from these cells without loss of viability,
whereas incubation with even low concen-
trations of C3a results in death ofthe cells
(Schorlemmer, Davies and Allison, 1976;
Schorlemmer and Allison, 1976). This
observation prompted an investigation of
the effects of C3a on murine and human
lymphocytes and tumour cells and lym-
phoblastic cells in culture, which has
shown that C3a in low concentrations
has cytotoxic effects on a variety of
normal and malignant cells.
MATERIALS AND METHODS
Preparation of complement components.-
Guinea-pig C3 and the cleavage product C3b
were prepared as previously reported (Bitter-
Suermann et al., 1970; Nicholson et al., 1975).
For generation and purification ofC3a, highly
purified C3 was cleaved by trypsin (1 mg/ml)
and, 1 min later, the reaction was stopped by
addition of soybean trypsin inhibitor (4 mg/
ml). In other experiments, C3 was incubated
with the C3 cleavage complex which is
formed when cobra venom factor interacts
with factor B, factor D and Mg++. In both
cases the reaction mixtures were passed
through Sephadex G100 columns. The
fractions which mediated contraction of
isolated guinea-pig terminal ileum wereCYTOTOXICITY OF C3a
pooled and concentrated. Cobra venom
factor (CVF) was purified by the method of
Bitter-Suermann et al. (1972). In most ofthe
present experiments, C3a prepared with
trypsin was used, but very similar results
were obtained with C3a prepared by the C3
cleavage complex CVF-B-D-Mg++.
Target cells.-Target cells were: P-815
cells, a chemically induced mastocytoma in a
DBA/2 mouse (Dunn and Potter, 1957);
L-cells, a mouse fibroblast-like cell line; D-55
cells, a derivative of 3T3 Swiss mouse cells
originally described by Todaro and Green
(1963); the C-243 line, originating from an
agar colony of D55 cells transformed by
murine sarcoma virus (MSV) (Bassin, Tuttle
and Fischinger, 1970); lympb node cells
obtained from mesenteric lymph nodes of
BALB/c mice; Chang cells, a human liver
epithelial-like cell line (Chang, 1954); and
CLA-4 cells, a human B-lymphoid cell line
(Steel, 1972). Human peripheral blood lym-
phocytes were from buffy coat residues left
after platelet removal from normal human
blood. Lymphocytes were separated by
Ficoll-Triosil density-gradient, centrifugation
(Boyum, 1968). They were cultured in
RPMI 1640 medium with 10% foetal bovine
serum, ata concentration of 7-5 x 105/ml and
stimulated with 1 ,ug/ml of purified phyto-
haemagglutinin (Wellcome) (PHA) for 4 days.
The above cell lines were maintained in the
same medium.
Labelling of cells.-The lysis of the cells
was assessed by the release of radioactive
chromium from the labelled cells by the
method of Brunner et al. (1970) and occa-
sionally compared with the trypan blue
exclusion test. For labelling of cells which
grew in suspension cultures, 5 x 106 cells
suspended in 1 ml of RPMI 1640 medium
were incubated with 0-1 mCi [51Cr]-sodium
chromate, alone or together with 0 1 mCi
[86Rb]-rubidium chloride (The Radiochemical
Centre, Amersham) for 1 h at 37°C. The cells
were washed x 4 and resuspended at a
concentration of 3.5 x 105/ml of RPMI
medium containing 0-1% crystallized bovine
serum albumin (BSA) (Sigma). Purified BSA
was used instead ofthe whole serum, because
of presence in the latter of an inactivator of
C3a, a carboxypeptidase (Bokisch and Muller-
Eberhard, 1970). In some experiments, BSA
was omitted from the medium, but the tubes
used in the cytotoxicity tests were rinsed with
0.1% BSA and then x 3 with phosphate-
buffered saline (PBS) and spun to remove the
liquid. Such treatment reduced an excessive
spontaneous release of the labels from the
cells, which occurred in the absence ofprotein.
Monolayers of L-cells, D-55, C-243 and
Chang cells were labelled with the same
concentration of sodium chromate in tissue
culture flasks, rinsed x 4 with PBS without
Ca and Mg and then treated with 0.02%
EDTA in PBS, pH 7 4, at 37°C for 5-10 min
to detach the cells, which were washed and
suspended in the RPMI medium; clumped
cells were removed by sedimentation.
Cytotoxicity assay.-In the cytotoxicity
tests 3-5 x 104 cells in 0 1 ml medium were
mixed with various concenltrations of C3
products in 0-02 ml medium in round-bottom
plastic tubes (7 5 x 1 cm) and the tubes
gassed with air containing 5% CO2. After
incubation at 37°C for the indicated times,
1 ml of Eagle's basal medium with 5% foetal
bovine serum was added to the tubes, the
cells centrifuged, and 0*5-ml samples of the
supernatants taken for counting of radio-
activity. The percent specific release of the
labels from the cells produced by C3 deriva-
tives, was calculated as follows:
Label released in the presence ofthe
agent - label released in its absence x 100
Total label incorporated - label
released in the absence of the agent
The percentage of the labels released by
freezing and thawing the cells twice is
indicated in the figures. Where stated, the
amounts of the labels released by freezing
were used, instead of the total incorporated,
for the calculation of percent release. The
values presented are means of duplicates and
the range of variation is indicated. Sponta-
neous Cr release in the absence of added
agents ranged between 6 and 26%, depending
on the target cell type.
RESULTS
Cytolytic effect of C3a on various cell types
In several independent experiments,
various types of cell were tested for their
susceptibility to C3a, prepared by trypsin
cleavage of the complement component
C3. Fig. 1 shows that all of the 5 cell
types of mouse origin tested were lysed
completely or nearly completely by C3a
in 6 h. Mastocytoma cells appeared to be
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FIG. 1.-Lysis of various mouse cell types by C3a in 6 h. *-mastocytoma cells; E-lymph node
cells, *-L-cells, 0-0-243 cells, *-D-55 cells. % label released by freezing and thawing the
cells is indicated by the symbols on the ordinate.
the most sensitive, 1-2 ,tg/ml of C3a
producing 50% lysis and 3-7 ,ug/ml lysis
comparable to that observed after freezing
and thawing. With higher doses of C3a
the Cr release exceeds that produced by
freezing and thawing. This was the case
also with the lymph node cells. D-55 cells
and their MSV-transformed derivative,
C-243 cells, were lysed to a comparable
extent, whereas L-cells were the least
susceptible, not reaching the frozen con-
trol level even with 100 jtg of C3a/ml. In
another experiment, the effect of C3a on
mastocytoma cells was assessed by com-
paring the Cr release with trypan blue
exclusion of the surviving cells (Table I).
There was a satisfactory agreement in
values obtained by the two tests, provided
that the percent Cr release was calculated
by comparison with frozen cells.
In Fig. 2, the data on the lysis of 4
cell types of human origin are presented.
C3a lysed CLA-4 cells and Chang cells to
the same extent as lymphocytes stimu-
lated with PHA, which were also com-
pletelylysed, whereas non-stimulated lym-
phocytes proved to be much more resist-
ant.
Effects ofC3and two ofitscleavageproducts,
C3b and C3a
In further experiments, purified native
C3, as well as its cleavage products C3a
and C3b, were tested on mastocytoma
cells. C3a was prepared by two different
methods, employing trypsin or cobra
venom factor, respectively. Cobra venom
factor itselfwas also included as a control.
As shown in Fig. 3, only C3a was found
to be cytolytic, and the products prepared
by the two methods did not differ appreci-
ably in their activity. An indication of
TABLE I.-Comparison between the Release of Chromium and Trypan Blue
Exclusion by the Mastocytoma Cells Treated with C3a
% 51Cr release based on:
Total incorporated
77-7±0-4
52-2+1.5
8-60-3
Releasable by freezing
98 6±0-5
66-2±2*0
10-9±0-3
100- % cells excluding
trypan blue
98.0+1*0
58-8±3-3
15-3±6- 7
Incubation time, 1 h. Concentration of trypan blue, 0 2%.
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FIG. 2.-Lysis of human cells by C3a in 6 h. 0-unstimulated lymphocytes, *-PHA-stimulated
lymphocytes, O-CLA-4 cells, A-Chang cells. Symbols on the ordinate indicate the freezing
and thawing controls.
the potency of C3a as a tumorolytic agent
is given by comparison with lysolecithin
(Sigma), the latter being less active even
on a weight basis. Expressed on a molar
basis, C3a is much more active.
Time course ofRb and Cr release from cells
by C3a
In several experiments, labelled Rb, a
potassium analogue, was used to deter-
mine whether a small-ion marker would
be released from the injured cells more
0
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rapidly than a larger marker such as Cr.
This would indicate that the lysis is due
to osmotic effects, as appears to be the
case with complement lysis and T-lympho-
cyte-mediated lysis (Burakoff, Martz and
Benacerraf, 1975; Ferluga and Allison,
1974). The time dependence of the
release of 864b and 51Cr in mastocytoma
cells incubatAd with C3a is illustrated in
Fig. 4. Specific release of Rb as well as
Cr reached about 40% in 7-5 min and was
completed in 30 min, with 20 ,tg/ml of
Concentration (,ugfml)
FIG. 3.-The effect of C3, its cleavage products and other agents on mastocytoma cells. O-C3a
prepared with cobra venom factor, *-C3a prepared with trypsin, A-3b, A-cobra venom
factor, f-]lysolecithin, *-C3. Time of incubation, 6 h.
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C3a. A lower concentration (13 ,ug/ml)
produced more gradual release of the
markers. The specific release of Rb pre-
ceded that of Cr by about 5 min. Such a
relatively short time interval between
the release of a small and a large marker
would indicate that the cells, after being
lethally hit, undergo lysis very rapidly.
Very similar results were obtained with
CLA-4 cells.
Temperature dependence ofcell lysis by C3a
The effects of temperature on the rate
of release of 86Rb and 51Cr from cells in
the presence of C3a axe shown in Fig. 5.
Mastocytoma cells incubated with 20
4'
I
0. u0-0
,tg/ml C3a at 370C for 1 h, showed nearly
complete release of both markers. The
release of both markers was much less in
cells kept at 9°C for i h. However, when
the cells were incubated with C3a at 3700
for 7-5 min, and then kept at 90C for the
remainder of the hour, a high proportion
of both labels was still released. These
results suggest that, in cells maintained
at relatively low temperature, C3a is
unable to exert its lytic effect. Neverthe-
less, brief exposure of the cells to 03a at
higher temperature increases the permea-
bility ofthe membrane in such a way that
a subsequent fall in temperature cannot
reverse it. The effect of temperature on
Time (min)
FIG. 4.-Time course of rubidium (Rb) and chromium (Cr) release from mastocytoma and CLA-4
cells by C3a. (A)-mastocytoma cells: solid lines, 20 ,ug C3a/ml, broken lines, 13-3 ,ug/ml.
(B)-CLA-4 cells: 40 ,ug C3a/ml. 0, %Rb: 0, %Cr.
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FIG. 5.-The influence of temperature on the release of the markers from the cells by C3a. % specific release ofRb (*) and Cr (0) from A, mastocytoma cells with 20 ,ug C3a/ml and B, CLA-4
cells with 40 ,ug C3a/ml. Solid lines, the test tubes kept at 370C; broken lines, at 9°C for the
times indicated.
the lysis ofCLA-4 cells was similar to that
observedwith mastocytomacells, although
the differences were less pronounced.
There was some lysis of CLA-4 cells
maintained with C3a at 900, although this
was much less than at 3700. When the
cells were incubated at 3700 for 10min
and transferred to 90C, the lysis was
almost stopped at the level reached in
10 min.
Effect of serum and serum-albumin on the
cell lysis by C3a
Because serum is reported to contain
an inactivator of O3a, carboxypeptidase B
(Bokisch and Muller-Eberhard, 1970),
43
guinea-pig serum, from which our C3a
was derived, was tested for its effect on
lysis mediated by C3a. In the presence
of fresh guinea-pig serum, the lytic effect
of 2'8 ,ug C3a was reduced to about a
quarter of that observed in the absence
ofserum, and there was nearly a complete
inhibition with lower doses of C3a (Table
II). If an enzyme were involved in
inactivation of C3a, it would be expected
that incubation of C3a with serum for 3 h
at 370C would result in further reduction
of its cytolytic capacity. However, such
preincubation in 50% serum resulted in
less inhibition of cytolysis. Similar results
were obtained in other experiments. They
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TABLE II.-The Effect ofSerum and Serum-albumin (BSA) on the Lysis of
Mastocytoma Cells by C3a, Measured as % Specific 51Cr Release
a Incubation in presence of
Nil (control)
0* 3*
70-1±0-4 69-5±0-5
68-5±0-8 66-9±2-7
5-2±2-0 6-1±1-4
17 3±1-3
Guinea-pig serum (14% final) BSA 0*1% BSA 1 0o%
0 3 0 0
18-4±0(73*8)t 33-7±2.5(51.5) 72-9±1-8 71-7±1-2
2-8±0-1 (95-9) 8-3±0-6 (87.6) 69-9±2-0 63-6±1,-5
0-5±0-1 (90.4) 2-7±0-1 (55.7) 14-2±0-5 16-8±0-4
13-2±0-2 14-2±0-2 13-1±0-2
2 - 8, 1 *4 or 0 7 ,ug of C3a in 20 ,1l RPMI medium were mixed with 20 ,ul of fresh guinea-pig serum, to
which 100 ,ll of 51Cr-labelled mastocytoma cell suspension was added, either immediately or after pre-
incubating the C3a-serum mixtures at 37°C for 3 h, and the samples incubated for 1 h in the cytotoxicity
test. Tubes for control and serum samples were rinsed with 0 - 1 % BSA.
* Preincubation time (h).
t Numbers in parentheses, % inhibition by serum.
Label released by freezing and thawing, 72 2 ± - 3%.
suggest that, if C3a is modified by the
action of serum enzymes (e.g. carboxy-
peptidase B), it is converted to a deriva-
tive or derivatives which are still cytolytic.
In any case, the presence of even high
concentrations of serum does not abolish
the capacity of C3a to lyse tumour cells.
DISCUSSION
These results establish that the com-
plement cleavage product C3a is lytic for
all the cell types tested, including several
transformed cells of human and mouse
origin. Our previous work (Schorlemmer
and Allison, 1976) established that incu-
bation with C3a kills mouse and guinea-
pig macrophages, so the cytolytic effect
may be exerted against a wide range of
cell types. The lysis by C3a is highly
efficient, concentrations of 1 to 10 ,ug/ml
killing the majority of exposed cells. All
the cells tested were sensitive to some
degree, although normal human lympho-
cytes were relatively resistant. Macro-
phages show intermediate sensitivity to
lysis by C3a. Hence, if small amounts of
C3a were generated (1-10 jtbg/ml) tumour
cells would be lysed, while macrophages
and lymphocytes would be spared. Such
differential effects could be important in
immunity against tumours.
The concentration of C3a required for
cytolysis is somewhat less than that
reported to be required for mast cell
degranulation (calculated from data of
Cochrane and Miiller-Eberhard, 1968).
C3a-mediated mast cell degranulation
occurs in vivo (Lepow et al., 1970), so it is
reasonable to suppose that the concentra-
tions of C3a generated in vivo could have
tumorolytic effects. Indeed, C3 circulates
in large quantities (1.23 mg/ml), and if all
were converted to C3a, the total amount
in human plasma would be of the order
of 50 ,tg/ml (Kohler and Muller-Eberhard,
1967). It is reported that C3a is inacti-
vated by carboxypeptidase B which is
present in serum (Bokisch and Muller-
Eberhard, 1970). However, once the
carboxy-terminal of C3a had reacted with
membrane constituents, it would presum-
ably be inaccessible to carboxypeptidase.
In our experiments, incubation of C3a
with fresh serum did not abolish its
capacity to lyse cells, possibly because a
cleavage product of C3a is still cytolytic.
The generation ofC3a could be through
the classical or alternative pathways of
complement activation, or through enzy-
matic cleavage of C3 by products of
activated macrophages (Schorlemmer and
Allison, 1976). Tumour cells release
proteinases, including plasminogen acti-
vator (Rifkin et al., 1974); the active
enzyme produced, plasmin, is known to
cleave C3, with liberation ofC3a (Bokisch,
Muller-Eberhard and Cochrane, 1969).
Thus it is conceivable that C3a plays a
role in immunity against tumour cells,
including that mediated by macrophages.
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It is also possible that C3a contributes to
damage of normal cells observed in some
immunopathological processes when com-
plement is activated, including some
autoimmune reactions. Animals depleted
of C3 for long periods (Pryjma and Hum-
phrey, 1975) should be useful for analysing
the role of C3a in protection against
tumours and in immunopathology. How-
ever, C3 is produced by mononuclear
phagocytes (Lai A Fat and van Furth,
1975) and may be liberated locally, even
when serum C3 is depleted.
It would be interesting to examine
C5a, the classical anaphylatoxin, for its
possible cytolytic effect, since it is also a
basic polypeptide with very similar bio-
logical properties to that ofC3a (Lieflander
et al., 1972). It is possible that C3a is the
same as certain soluble factors which
have rapid cytolytic effects, e.g. cytotoxic
products from activated macrophages
(Sethi and Brandis, 1975; Currie and
Basham, 1975). Macrophages secrete C3
and an enzyme that can cleave it (Schor-
lemmer and Allison, 1976) and could,
independently of serum constituents, gen-
erate C3a when appropriately stimulated.
The mechanism by which the lysis is
brought about is not yet known. The
well known effects of C3a on mast cell
degranulation and contraction of smooth
muscle are presumably due to increased
permeability of plasma membranes to
ions, especially Ca++ (ter Laan et al.,
1974). The structure of C3a is known
(Hugli, 1975): the polypeptide chain has
an unusually cationic C-terminal region.
The structure is that of an amphipathic
molecule, which could become partially
inserted into a membrane, with its C-
terminal region interacting ionically with
acidic glycoproteins and possibly glyco-
lipids. Our observations show that incu-
bation of cells with C3a makes their
plasma membranes more permeable to
ions such as Rb+, an analogue of K+
using the samne active transport system.
If there is also increased influx of Na+
in excess of the active transport system,
osmotic lysis would result. The fact that
86Rb+ is released from cells before 51(Cr
even by a relatively short interval, is
consistent with osmotic lysis.
When cells are maintained in the
presence of C3a at 9°C, there is little lysis,
perhaps because C3a is unable to penetrate
the membrane, which is rather rigid at
that temperature; it is known that at
37-40°C membrane lipids are predomi-
nantly in a liquid phase, whereas at
9-10°C they are more closely packed in a
regular hexagonal array (Engelman, 1970).
When mastocytoma cells have been incu-
bated in the presence of C3a for a few
minutes at 37°C and then transferred to
9°C, loss of 86Rb and 51Cr continues,
suggesting that once C3a is inserted on to
the membrane, the increased ion flux
cannot be reversed at low temperature.
In contrast, the increased ion permeability
produced in mastocytoma cells by T-
lymphocytes was reversed at 10°C (Fer-
luga and Allison, 1974). Hence the two
membrane lesions appear to be different.
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